Please login to the form below

Not currently logged in
Email:
Password:

Pharma market access [infographic]

A 12 step process for preparing a pharma brand for market

Pharma market access infographic

There is no 'one' definition of market access – the idea of which varies from company to company; region to region.

But while there may not be consensus on the exact wording – which spans everything from 'stakeholders' to 'accelerate market uptake', 'optimising value' and 'pricing and reimbursement' – most agree that it is not a 'discipline' that can be packaged neatly into a silo.

Inside: Market Access, a new publication from PMLiVE's publishers PMGroup, provides expert thinking on the area and includes a unique market access road map.

Download full size infographic on 12 steps to prepare a pharma brand for market (pdf - right click and select 'save link as')

Pharma market access reportThe publication, which PME subscribers received earlier this month, also looks at:

• Re-positioning pharma's image for market access success
• How to equip market access teams for local challenges
• The role of communication and education
• The true meaning of market access
• UK market access and the NHS
• How NICE is collaborating, and exporting its thinking, across Europe and beyond
• EU pricing and reimbursement, and reference pricing.

View Inside: Market Access online

28th June 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Reynolds-MacKenzie

Reynolds-MacKenzie is the multi award-winning specialist public relations practice within OPEN Health; the first ever agency in the health communications...

Latest intelligence

The patient will see you now
GCI Health’s Laura Starr and Chris Bath report on how the dawning era of mobile tech and the ‘Internet of Things’ has transformed the health and wellness arena....
When forecasters take the floor: 6 tips on presenting a forecast
Peter Mansell queries some of pharma’s leading forecasters for their dos and don’ts on presenting a forecast...
Enablers of drug innovation could lie in the numbers
Christopher Ehinger of Black Swan Analysis addresses the problem of clinical-trial recruitment as a barrier to new drug development and offers a new way of looking at the problem....

Infographics